🇺🇸 FDA
Pipeline program

Pacritinib

381401

Phase 2 mab terminated

Quick answer

Pacritinib for Primary Myelofibrosis is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Primary Myelofibrosis
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials